Inoue Hiroshi K, Sato Hiro, Suzuki Yoshiyuki, Saitoh Jun-ichi, Noda Shin-ei, Seto Ken-ichi, Torikai Kota, Sakurai Hideyuki, Nakano Takashi
Cyber Center, Kanto Neurosurgical Hospital, 1120 Dai, Kumagaya, Saitama, 360-0804, Japan.
Neurosurgery and Radiation Oncology, Institute of Neural Organization, 1120 Dai, Kumagaya, Saitama, 360-0804, Japan.
Radiat Oncol. 2014 Oct 17;9:231. doi: 10.1186/s13014-014-0231-5.
A single-institutional prospective study of optimal hypofractionated conformal radiotherapy for large brain metastases with high risk factors was performed based on the risk prediction of radiation-related complications.
Eighty-eight patients with large brain metastases ≥10 cm(3) in critical areas treated from January 2010 to February 2014 using the CyberKnife were evaluated. The optimal dose and number of fractions were determined based on the surrounding brain volume circumscribed with a single dose equivalent (SDE) of 14 Gy (V14) to be less than 7 cm(3) for individual lesions. Univariate and multivariate analyses were conducted.
As a result of optimal treatment, 92 tumors ranging from 10 to 74.6 cm(3) (median, 16.2 cm(3)) in volume were treated with a median prescribed isodose of 57% and a median fraction number of five. In order to compare the results according to the tumor volume, the tumors were divided into the following three groups: 1) 10-19.9 cm(3), 2) 20-29.9 cm(3) and 3) ≥30 cm(3). The lesions were treated with a median prescribed isodose of 57%, 56% and 55%, respectively, and the median fraction number was five in all three groups. However, all tumors ≥20 cm(3) were treated with ≥ five fractions. The median SDE of the maximum dose in the three groups was 47.2 Gy, 48.5 Gy and 46.5 Gy, respectively. Local tumor control was obtained in 90.2% of the patients, and the median survival was nine months, with a median follow-up period of seven months (range, 3-41 months). There were no significant differences in the survival rates among the three groups. Six tumors exhibited marginal recurrence 7-36 months after treatment. Ten patients developed symptomatic brain edema or recurrence of pre-existing edema, seven of whom required osmo-steroid therapy. No patients developed radiation necrosis requiring surgical resection.
Our findings demonstrate that the administration of optimal hypofractionated conformal radiotherapy based on the dose-volume prediction of complications (risk line for hypofractionation), as well as Kjellberg's necrosis risk line used in single-session radiosurgery, is effective and safe for large brain metastases or other lesions in critical areas.
基于对放射相关并发症的风险预测,开展了一项针对具有高风险因素的大脑大转移瘤的最佳低分割适形放疗的单机构前瞻性研究。
对2010年1月至2014年2月期间使用射波刀治疗的88例关键区域大脑转移瘤体积≥10 cm³的患者进行评估。根据单个病灶周围脑体积的单剂量等效值(SDE)为14 Gy(V14)小于7 cm³来确定最佳剂量和分割次数。进行单因素和多因素分析。
经过最佳治疗,92个体积从10至74.6 cm³(中位数为16.2 cm³)的肿瘤接受了治疗,处方等剂量中位数为57%,分割次数中位数为5次。为了根据肿瘤体积比较结果,将肿瘤分为以下三组:1)10 - 19.9 cm³,2)20 - 29.9 cm³和3)≥30 cm³。三组病灶的处方等剂量中位数分别为57%、56%和55%,三组的分割次数中位数均为5次。然而,所有体积≥20 cm³的肿瘤均接受了≥5次分割。三组中最大剂量的SDE中位数分别为47.2 Gy、48.5 Gy和46.5 Gy。90.2%的患者实现了局部肿瘤控制,中位生存期为9个月,中位随访期为7个月(范围3 - 41个月)。三组之间的生存率无显著差异。6个肿瘤在治疗后7 - 36个月出现边缘复发。10例患者出现有症状的脑水肿或原有脑水肿复发,其中7例需要使用渗透压性类固醇治疗。没有患者发生需要手术切除的放射性坏死。
我们的研究结果表明,基于并发症剂量 - 体积预测(低分割风险线)以及单次放射外科手术中使用的凯尔伯格坏死风险线进行最佳低分割适形放疗,对于大脑大转移瘤或关键区域的其他病灶是有效且安全的。